Fig. 3: Neutralization efficiency of serum antibodies against authentic SARS-CoV-2. | Cell Discovery

Fig. 3: Neutralization efficiency of serum antibodies against authentic SARS-CoV-2.

From: COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan

Fig. 3: Neutralization efficiency of serum antibodies against authentic SARS-CoV-2.The alternative text for this image may have been generated using AI.

a NAb titers against the authentic SARS-CoV-2 WIV04, Delta, and Omicron BA.1 and BA.2 strains in the hybrid-immunity group at 1–3, 4–6, 7–9, and 10–12 months post vaccination and in the infection-only group. The dotted line represents the limit of detection (1:8); below the limit of detection, values were set to 1:1. Error bars represent the GMT values with 95% confidence intervals, and the colored numbers in the figures represent GMT values. Statistical significance was analyzed using the Kruskal–Wallis test. b GMT values against the authentic SARS-CoV-2 strains in the infection-only group and hybrid-immunity group (one, two, three, and all doses, at 1–3 months post vaccination). c–g Correlation between NAb titers (GMT) against WIV04 (c), Delta (d), Omicron BA.1 (e), BA.2 (f), and BA.5 (g) and RBD-IgG titers in the infection-only (left) and hybrid-immunity (right) groups. Scatter plots represent a simple linear fit with 95% confidence bands, together with the Spearman correlation coefficient and 2-tailed P value. h The ratio of authentic SARS-CoV-2 NAb titers (IC50) to RBD-IgG titers (dilution quantitative) was calculated as a neutralization potency index. Data are means ± SD. Statistical significance was analyzed using the paired t-test. WIV04, SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/2019; MPV, months post vaccination.

Back to article page